Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating the Safety, Tolerability, and Efficacy of Pirfenidone and PD-1 Inhibitor With or Without Hypofractionated Radiotherapy in Patients With Advanced, Refractory pMMR/MSS Colorectal Cancer

NCT07644286 is registered in ClinicalTrials.gov with Tao Zhang as lead sponsor.

NCT NCT07644286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07644286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating the Safety, Tolerability, and Efficacy of Pirfenidone and PD-1 Inhibitor With or Without Hypofractionated Radiotherapy in Patients With Advanced, Refractory pMMR/MSS Colorectal Cancer
Lead sponsor
Tao Zhang
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2025
Completion date
December 25, 2027
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc)